Roivant Sciences Ltd. (NASDAQ: ROIV) announced positive Phase 2 results for brepocitinib in cutaneous sarcoidosis and reported financial results for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE